Bhattacharya Anindya, Schenck Kathryn W, Xu Yao-Chang, Nisenbaum Laura, Galbreath Elizabeth, Cohen Marlene L
Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, Indiana, USA.
J Pharmacol Exp Ther. 2004 May;309(2):825-32. doi: 10.1124/jpet.103.062653. Epub 2004 Jan 14.
This study characterizes the sumatriptan-sensitive [5-hydroxytryptamine (5-HT)(1B/1D)] receptor in rabbit saphenous vein and basilar artery. (S)-(-)-1-[2-[4-(4-Methoxy-phenyl)-piperazin-1-yl]-ethyl]isochroman-6-carboxylic acid methylamide (PNU-109291), a 5-HT(1D) subtype-selective agonist (human K(i) = 2.5 +/- 0.07 nM), did not contract either tissue, whereas o-methoxyphenylpiperazide derivative 4F (MPPA-4F), a 5-HT(1B) subtype-selective antagonist (human K(i) = 4.6 +/- 0.6 nM) potently inhibited sumatriptan-induced contraction in the saphenous vein and basilar artery. These results suggested that sumatriptan-induced contraction was mediated via the 5-HT(1B) receptor in these blood vessels. 5-HT(1B) receptor-mediated contraction was then compared in endothelium-intact and denuded vessels to evaluate the role of the endothelium in regulating sumatriptan-induced contractility in these tissues. The presence of an intact endothelium inhibited 5-HT(1B)-induced contraction in both tissues. Endothelial denudation or nitric-oxide synthase inhibition with N(omega) nitro-L-arginine methyl ester (L-NAME) (100 microM) increased the efficacy and potency of sumatriptan in the saphenous vein and basilar artery. Surprisingly, in endothelial-denuded vascular tissues, L-NAME (100 microM) also significantly increased the maximal 5-HT(1B) receptor-induced contraction in both tissues, with no effect on potency of sumatriptan. The effect of L-NAME after endothelial denudation may reflect the presence of a low density of residual endothelial cells as estimated by CD31 antibody staining combined with the modulating effect of nitric oxide released from nonendothelial cells in vascular tissue. Endothelial modulation was specific to 5-HT(1B) receptors because removal of the endothelium did not significantly alter contraction to norepinephrine, histamine, prostaglandin, or potassium chloride in the saphenous vein or basilar artery.
本研究对兔隐静脉和基底动脉中对舒马曲坦敏感的[5-羟色胺(5-HT)(1B/1D)]受体进行了表征。(S)-(-)-1-[2-[4-(4-甲氧基苯基)-哌嗪-1-基]-乙基]异苯并二氢吡喃-6-羧酸甲酯(PNU-109291),一种5-HT(1D)亚型选择性激动剂(人K(i)=2.5±0.07 nM),对两种组织均无收缩作用,而邻甲氧基苯基哌嗪衍生物4F(MPPA-4F),一种5-HT(1B)亚型选择性拮抗剂(人K(i)=4.6±0.6 nM),能有效抑制舒马曲坦诱导的隐静脉和基底动脉收缩。这些结果表明,舒马曲坦诱导的收缩是通过这些血管中的5-HT(1B)受体介导的。然后比较了内皮完整和去内皮血管中5-HT(1B)受体介导的收缩情况,以评估内皮在调节这些组织中舒马曲坦诱导的收缩性中的作用。完整内皮细胞的存在抑制了两种组织中5-HT(1B)诱导的收缩。内皮剥脱或用N(ω)硝基-L-精氨酸甲酯(L-NAME)(100μM)抑制一氧化氮合酶可增加舒马曲坦在隐静脉和基底动脉中的效力和效能。令人惊讶的是,在去内皮的血管组织中,L-NAME(100μM)也显著增加了两种组织中5-HT(1B)受体诱导的最大收缩,而对舒马曲坦的效能无影响。内皮剥脱后L-NAME的作用可能反映了通过CD31抗体染色估计的低密度残余内皮细胞的存在,以及血管组织中非内皮细胞释放的一氧化氮的调节作用。内皮调节对5-HT(1B)受体具有特异性,因为去除内皮并未显著改变隐静脉或基底动脉中对去甲肾上腺素、组胺、前列腺素或氯化钾的收缩反应。